InterVene Secures Financing for Recana Venous System

October 7, 2024—InterVene, Inc., a clinical-stage medical device company that is developing interventional solutions for chronic venous insufficiency, announced the closing of its Series A financing round of $13 million.

According to the company, proceeds from the round will fund the final development of the company’s Recana catheter system, including initiation of clinical cases, regulatory submission, and market clearance in the United States. In addition, proceeds will support preparation for initial commercialization and postmarket clinical research of the device.

InterVene stated that Recana has been designed to recanalize and restore patency in chronically obstructed deep veins and venous stents, particularly when recanalization capabilities are limited or when long-term chronic stent maintenance is necessary.

Utilizing standard fluoroscopy-/intravenous ultrasound–guided interventional techniques, Recana can be incorporated by vascular specialists already performing deep vein thrombosis (DVT) treatment and deep venous stenting.

The financing was led by new investor Treo Ventures and existing investor RiverVest Venture Partners. In conjunction with this financing, Brad Vale, Treo Ventures founding general partner, has joined InterVene’s Board of Directors.

Professor Stephen Black, MD, who is a venous surgery physician at King’s College, London, a consultant vascular surgeon at Guy’s & St. Thomas’ Hospital in London, United Kingdom, and an advisor to InterVene, discussed Recana in the company’s press release.

“With the dramatic growth of venous interventions, DVT thrombectomy, and venous stents, experience has made us more aware of the causes and often life-long impact of deep venous obstruction and occlusion as well as a need for reinterventions in many patients,” commented Prof. Black. “This is especially prevalent before and after treatment in post-thrombotic patients and the challenging problem of in-stent restenosis. Recana will be a valuable tool for recanalization in these settings and offers new treatment options for patients requiring ongoing care.”